SYK · STRYKER CORP

402 filings

SYK SEC Filings

STRYKER CORP - 402 total filings

Filing record · 2016–202610-K1110-Q328-K125

Showing 1–50 of 402 filings

STRYKER CORP 8-K Report, Executive Changes (Oct 6, 2026)

On October 6, 2026, Stryker (NYSE: SYK) announced a planned CEO succession. Kevin Lobo, CEO since October 2012 and Chair since July 2014, will step down as CEO on December 31, 2026 and become Executive Chair of the Board effective January 1, 2027. Spencer Stiles, the company's President and COO since January 2026, will succeed him as CEO on the same date and join the Board, which expands from 10 to 11 members. The Board frames the change as the culmination of a long-term succession process, and Lobo's transition agreement keeps his base salary, bonus target and benefit eligibility unchanged, though he will receive no new stock awards as Executive Chair. For Stiles, the 8-K sets a base salary of $1,320,000 and a bonus target of 150% of base salary from January 1, 2027. The Board will also be asked to approve a February 2027 equity grant with an aggregate target grant date fair value of $14.2 million, split 40% stock options and 60% performance stock units. Investors should note that the filing does not specify a stock option strike price methodology or exercise terms beyond the standard five-year annual vesting for options, and it discloses no committee assignments for Stiles yet. The transition is planned and orderly, with a seven-month handover period before the effective date. The key open questions for investors concern continuity of strategy and execution under new leadership, retention of key personnel, and whether the Executive Chair role leaves Lobo with meaningful influence over the company's direction. The press release's forward-looking statements flag these execution and retention risks explicitly.

Oct 6, 2026 10-Q

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2026

Stryker Corporation reported strong financial results for the second quarter and first half of 2026. Net sales increased by 9.4% year-over-year for the quarter and 6.1% for the six-month period, driven by robust unit volume growth across both the MedSurg and Neurotechnology, and Orthopaedics segments. This top-line growth translated into significant improvements in profitability. Operating income saw a substantial increase, rising to $1.66 billion for the quarter and $2.59 billion for the six months, up from $1.11 billion and $1.95 billion in the prior year periods, respectively. This expansion in operating income, coupled with a higher gross profit margin, led to a significant increase in net earnings, which grew by 44.3% for the quarter to $1.28 billion and 31.4% for the six months to $2.02 billion. Diluted EPS also saw a considerable jump, reflecting the strong earnings performance.

Jul 31, 2026 8-K

STRYKER CORP 8-K Report, Financial Results (Jul 30, 2026)

Stryker reported second quarter 2026 results that showed a strong rebound from the cybersecurity incident first disclosed on March 11, 2026. Net sales rose 9.4% to $6.6 billion, with organic growth of 9.0% driven by unit volume. MedSurg and Neurotechnology grew 9.7% reported (9.2% organic), and Orthopaedics grew 9.1% reported (8.6% organic). Reported EPS increased 44.1% to $3.30, and adjusted EPS increased 17.9% to $3.69. Adjusted operating margin expanded 170 basis points to 27.4%, while reported operating margin reached 25.2%. The headline earnings growth is flattered by low-quality items that investors should separate from the underlying trend. Reported results include a $158 million pre-tax benefit from the reversal of 2025 tariffs, which is excluded from adjusted figures and contributed roughly $0.34 per diluted share. Prior-year results also carried larger impairment and acquisition-related charges, which makes the year-over-year reported comparison look more favorable than the operating trend. Structural optimization and other special charges were $95 million in the quarter, mostly in the 'other charges' category, and the company's effective tax rate on a reported basis was 18.4%. Management narrowed full-year 2026 guidance to organic net sales growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10, and it expects a modestly positive pricing impact and a slightly favorable foreign exchange effect if rates hold. Six-month operating cash flow improved to $1.84 billion from $1.36 billion, and the company repaid $750 million of debt, though cash declined to $3.39 billion. Investors should monitor the pace of the cyber recovery in the second half, the durability of the tariff-related and tax benefits, and the ultimate cost of recall, regulatory and legal matters that the company flagged as uncertain.

Jul 30, 2026 8-K

STRYKER CORP 8-K Report, Corporate Update (Jun 26, 2026)

Stryker filed this Form 8-K on June 26, 2026 to recast its consolidated financial statements for 2023 through 2025 to reflect a change in segment reporting. The change is organizational, not an accounting restatement: the company is reorganizing its Instruments and Other Orthopaedics businesses into a new Ortho Tech business, which combines orthopaedic instruments with Mako robotics and enabling technologies. Stryker will still report two segments, MedSurg and Neurotechnology and Orthopaedics. Consolidated net sales, net earnings, the balance sheet, and cash flows are unchanged by the recast. The filing does not update the 2025 10-K's MD&A for later developments, so investors should read it alongside the Q1 2026 10-Q. The recast mainly changes how segment-level growth and margins look. Under the new structure, Ortho Tech 2025 net sales were $11,239 million, up 10.9% as reported, with Ortho Tech carrying the Mako robotics and power tool franchise. MedSurg and Neurotechnology remains the faster-growing segment at 16.5% reported growth in 2025, versus 5.4% for Orthopaedics, which was weighed down by the divestiture of Spinal Implants. Because the Spinal Implants business was sold in April 2025, the Orthopaedics comparison is distorted by that sale. Investors modeling segment economics should use the recast figures rather than the originally reported ones. The filing also reconfirms the 2025 financial baseline that the recast leaves intact: net sales of $25,116 million (+11.2%), GAAP diluted EPS of $8.40, adjusted diluted EPS of $13.63 (+11.8%), and operating cash flow of $5,044 million. Acquisitions, mainly Inari Medical for about $4.8 billion, were the largest use of capital, and total debt rose to $15,859 million. The filing does not change any of these figures. Its value lies in giving analysts a consistent segment basis for future comparisons.

Jun 26, 2026 8-K

STRYKER CORP 8-K Report, Executive Changes (May 20, 2026)

Stryker Corporation (SYK) announced a leadership transition in its accounting department, with Vice President and Chief Accounting Officer William E. Berry, Jr. retiring effective September 1, 2026. Emily Baculik, currently Vice President, Corporate Controller, will assume the role of Chief Accounting Officer starting the same date. This transition involves a planned advisory period for Mr. Berry and a compensation adjustment for Ms. Baculik as she steps into her new role. Investors should note the smooth handover facilitated by Mr. Berry's advisory role and the clear succession plan. Ms. Baculik brings extensive experience from various finance and accounting leadership positions within Stryker and other publicly traded companies. The filing details the terms of Mr. Berry's transition agreement, including continued salary and bonus eligibility, and Ms. Baculik's new compensation structure, which includes a base salary increase and potential long-term incentive awards.

May 20, 2026 10-Q

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2026

Stryker Corporation reported its first quarter 2026 results, showcasing a 2.6% increase in net sales to $6,020 million, driven by both its MedSurg and Neurotechnology segment (up 5.0%) and a marginal increase in its Orthopaedics segment (up 0.1%). While overall sales saw a modest rise, profitability faced some headwinds, with gross profit margin declining to 63.3% from 63.8% year-over-year, primarily due to increased manufacturing and supply chain costs linked to a recent cybersecurity incident. Net earnings rose to $745 million, or $1.93 per diluted share, a notable increase from $654 million, or $1.69 per diluted share, in the prior year period. Despite the challenges, including the impact of the cybersecurity incident, Stryker demonstrated resilience in its operations. The company's strategic focus on innovation and its diversified product portfolio across key medical technology areas continue to support its growth trajectory. Management highlighted a reorganization in the Ortho Tech business to enhance customer experience and speed to market. Investors will be keen to monitor the ongoing impact of the cybersecurity incident and the company's ability to navigate supply chain pressures and maintain its growth momentum in the upcoming quarters.

May 11, 2026 8-K

STRYKER CORP 8-K Report, Shareholder Vote Results (May 8, 2026)

Stryker Corporation (SYK) filed an 8-K on May 8, 2026, reporting the results of its Annual Meeting of Shareholders held on May 6, 2026. The primary focus of the filing is the voting outcomes on three key proposals: the election of directors, the ratification of the independent registered public accounting firm, and an advisory vote on executive compensation. All proposals received substantial shareholder support, indicating a positive sentiment from the company's investors regarding its governance and financial oversight. Specifically, all ten nominated directors were overwhelmingly elected, demonstrating continued confidence in the company's leadership. Shareholders also ratified the appointment of Ernst & Young LLP as the independent auditor for 2026, a standard but important vote for financial transparency. Furthermore, the advisory resolution on executive compensation was approved, suggesting that shareholders are largely in agreement with the company's compensation practices for its named executive officers.

May 8, 2026 8-K

STRYKER CORP 8-K Report, Financial Results (Apr 30, 2026)

Stryker reported first quarter 2026 results on April 30, 2026, with reported net sales up 2.6% to $6.0 billion and organic growth of 2.4%, driven by 2.1% unit volume growth and 0.3% pricing. The MedSurg and Neurotechnology segment grew reported sales 5.0% to $3.2 billion, with Vascular (+27.5% U.S.) and Instruments as standouts, while Orthopaedics was roughly flat reported (+0.1%) at $2.8 billion, with organic growth of 4.1% offset by the divestiture of Spinal Implants (down ~99%). Reported EPS rose 14.2% to $1.93, but adjusted EPS fell 8.5% to $2.60 and adjusted operating margin contracted 180 bps to 21.1%, reflecting pressure from a cyber incident first reported March 11, 2026, and related costs. Management reaffirmed full-year 2026 guidance of 8.0%–9.5% organic sales growth and adjusted EPS of $14.90–$15.10. Balance sheet and cash flow show a shift in capital allocation: cash fell to $2.9 billion from $4.0 billion, and long-term debt declined to $14.2 billion from $14.9 billion after $1.0 billion of net debt repayment. Operating cash flow improved to $581 million from $250 million, though working capital remained a drag, and acquisition spending dropped to $22 million versus $4.7 billion a year earlier. The company also reorganized its orthopaedics business into a new Ortho Tech unit and recast prior-period segment data, which affects comparability of segment trends. For investors, the key tension is between strong reported top-line and GAAP earnings growth, which benefited from lower acquisition-related and impairment charges, and a weaker underlying profitability picture on an adjusted basis. The reaffirmed guidance implies a significant ramp in the remaining quarters, so execution on the cyber recovery, margin recovery, and the Inari integration will be central to the investment thesis.

Apr 30, 2026 8-K

STRYKER CORP 8-K/A Report, Cybersecurity Incident (Apr 9, 2026)

This 8-K/A filing from Stryker Corp. (SYK) provides an important update regarding a material cybersecurity incident first disclosed in March 2026. The company confirms that the incident, which occurred on March 11, 2026, caused disruptions to its business operations. While an investigation is ongoing with the help of third-party experts and law enforcement, Stryker has determined the incident had a material impact on its operations and, consequently, its financial results for the first quarter of 2026. Despite the Q1 financial impact, Stryker believes the incident is not reasonably likely to materially impact its full-year 2026 guidance. As of the filing date, the company has fully restored operations across its global manufacturing network, and its commercial, ordering, and distribution systems are back online. Investors should note that the company plans to discuss these financial results and guidance components in more detail during its Q1 2026 earnings report scheduled for April 30, 2026.

Apr 9, 2026 8-K

STRYKER CORP 8-K Report, Regulation FD Disclosure (Mar 23, 2026)

Stryker Corporation (SYK) filed this Item 7.01 Regulation FD 8-K on March 23, 2026 to provide an update on a cybersecurity incident first disclosed in 8-Ks dated March 11 and March 12, 2026. Management says the threat actor used a malicious, non-self-propagating file to run commands and hide activity inside its systems. Per Palo Alto Networks Unit 42's General Assurance Letter (Exhibit 99.1, dated March 20, 2026), no persistent unauthorized access remains, known indicators of compromise have been addressed, and no evidence has been found of the attacker reaching customer, supplier, vendor, or partner systems. Stryker is rebuilding impacted systems or restoring them from pre-compromise backups, and systems not yet restored remain isolated from the network. The most important point for investors is that the financial impact is still unknown. Stryker explicitly states it has not yet determined whether the incident is reasonably likely to have a material impact on the company, and that the scope and operational and financial effects are still being assessed. The company's own website update (Exhibit 99.2) notes that manufacturing is ramping back up as critical lines and plants come back online, with restoration prioritized for systems supporting customers, ordering, and shipping. Operations are described as stabilizing but not fully restored. The filing is largely qualitative and contains no quantified revenue, cost, or cash-flow figures. Investors should watch for quantification of disruption in upcoming periodic reports (10-Q/10-K), any material-impact determination, possible litigation or regulatory scrutiny, and the pace of manufacturing and shipment recovery. The forward-looking statement language flags potential effects on revenue, operating income, cash flows, liquidity, and customer relationships.

Mar 23, 2026 8-K

STRYKER CORP 8-K Report, Regulation FD Disclosure (Mar 12, 2026)

Stryker Corporation (SYK) filed an 8-K on March 12, 2026, providing an update on a previously disclosed cybersecurity incident. This incident has impacted the Company's global Microsoft environment, leading to ongoing disruptions in critical operations such as order processing, manufacturing, and shipping. While patient-related services and connected products are not believed to have been affected, the full scope and financial impact of the incident remain under investigation and are currently unknown. Investors should be aware that the company is actively managing the situation, with the Chief Information Security Officer providing updates to stakeholders. However, the material operational and financial consequences are yet to be determined. The filing includes cautionary statements regarding forward-looking information, highlighting potential risks including data integrity issues, system restoration delays, and potential adverse effects on operations, financial condition, and relationships with third parties.

Mar 12, 2026 8-K

STRYKER CORP 8-K Report, Corporate Update (Mar 11, 2026)

Stryker Corporation (SYK) has disclosed a significant cybersecurity incident that occurred on March 11, 2026, impacting its global Microsoft environment and causing widespread disruption to its IT systems and business applications. The company has activated its cybersecurity response plan and is investigating the incident with the support of external experts. While initial indications suggest no ransomware or malware and that the incident is contained, the full scope, nature, and operational and financial impacts are still under investigation. Investors should note that the company is actively working to restore affected systems and has business continuity measures in place to maintain operations and support customers. However, the timeline for full restoration remains unknown, and Stryker has not yet determined if the incident will have a material impact. The company's forward-looking statements in the filing highlight potential risks including data integrity issues, restoration delays, operational disruptions, financial impacts, litigation, and reputational damage.

Mar 11, 2026 10-K

STRYKER CORP Annual Report, Year Ended Dec 31, 2025

Stryker Corporation reported strong performance for the fiscal year 2025, with net sales growing by 11.2% to $25,116 million, driven by robust increases in both its MedSurg and Neurotechnology segment (up 15.7%) and its Orthopaedics segment (up 4.3%). This growth was primarily fueled by increased unit volume across all businesses, with a notable contribution from the acquisition of Inari Medical, Inc. The company also demonstrated improved profitability, with gross profit increasing and operating income rising to $4,889 million, reflecting effective pricing strategies and favorable volume dynamics. Financially, Stryker maintained a healthy liquidity position, with significant cash flow from operations and substantial cash reserves. The company continued its capital allocation strategy, investing heavily in acquisitions totaling $4,960 million, while also returning capital to shareholders through dividends. Despite macroeconomic headwinds and ongoing investments in growth initiatives, Stryker has reaffirmed its commitment to innovation and expanding its product offerings, particularly in areas like robotic-assisted surgery and minimally invasive treatments, positioning it for continued success in the dynamic medical technology landscape.

Feb 11, 2026 8-K

STRYKER CORP 8-K Report, Financial Results (Jan 29, 2026)

Stryker reported fourth-quarter 2025 net sales of $7.2 billion, up 11.4% reported and 11.0% organic, with adjusted operating margin expanding 100 bps to 30.2%. Full-year sales reached $25.1 billion (up 11.2%, 10.3% organic), and adjusted EPS rose 11.8% to $13.63. MedSurg and Neurotechnology drove most of the growth, with Q4 sales up 17.5% reported and 12.6% organic, while Orthopaedics grew 8.4% organic in Q4 after a 7.5-point drag from divestitures. Spinal Implants sales fell sharply, which is the main soft spot in the segment detail. Reported results are distorted by non-recurring items. Q4 reported EPS of $2.20 (up 56%) includes a $589 million tax charge, or $1.53 per share, tied to the transfer of certain intellectual property between tax jurisdictions. Reported full-year EPS of $8.40 rose only 8.2% because of that charge, $173 million of inventory step-up, $335 million of other acquisition and integration costs (including $140 million of stock compensation payments on change in control), and the 2024 goodwill impairment comparison. Investors should anchor on adjusted figures, while recognizing that the adjustments are large and recurring in nature for an acquisitive company. For 2026, management guides to organic net sales growth of 8.0% to 9.5% and adjusted EPS of $14.90 to $15.10, implying roughly 9% to 11% adjusted EPS growth over $13.63. The balance sheet is more leveraged after acquisitions: long-term debt rose to $14.9 billion from $12.2 billion, and 2025 acquisitions consumed $5.0 billion of cash, with goodwill and intangibles up to $25.0 billion. Integration of Inari Medical, referenced in the forward-looking statements, is a key execution item for 2026.

Jan 29, 2026 8-K

STRYKER CORP 8-K Report, Executive Changes (Dec 4, 2025)

Stryker (NYSE: SYK) announced on December 4, 2025 a leadership succession that elevates Spencer Stiles to President and Chief Operating Officer, effective January 1, 2026. Stiles, a 27-year company veteran who has led Orthopaedics since 2019, will oversee the global businesses, strategy, and mergers and acquisitions, positioning him as a central figure in the company's growth agenda. The move is framed by CEO Kevin Lobo as a way to sustain high growth and leverage the breadth of Stryker's MedSurg, Neurotechnology, and Orthopaedics portfolio. To backfill the Orthopaedics role, Dylan Crotty, currently President of Instruments and also a 27-year Stryker veteran, will become Group President, Orthopaedics, effective the same date. The filing discloses a compensation step-up for both executives: Stiles's base salary rises to $1,000,000 with a 100% bonus target, and Crotty's rises to $700,000 with an 85% bonus target. The Compensation and Human Capital Committee will also be asked to approve February 2026 long-term incentive grants with aggregate target values of roughly $6 million for Stiles and $3 million for Crotty, split 40% stock options and 60% performance stock units. For investors, this is primarily a planned internal succession rather than a strategic shift or a financial event, and the filing contains no disclosed impact on guidance or financial results. The key signals are continuity, since both successors are long-tenured insiders, and the enhanced incentive structure, which ties a larger share of executive pay to multi-year performance. The stated M&A responsibility for the new COO is worth monitoring, as it may signal a greater role for acquisitions in Stryker's future capital allocation.

Dec 4, 2025 10-Q

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2025

Stryker Corporation reported a solid third quarter for fiscal year 2025, with net sales increasing by 10.3% year-over-year to $6.06 billion. This growth was driven by a robust 9.6% increase in constant currency, with nearly all segments contributing to higher unit volumes. The MedSurg and Neurotechnology segment showed particularly strong performance, with a 14.4% reported sales increase, bolstered by the recent acquisition of Inari Medical. The Orthopaedics segment also saw positive growth, albeit at a more moderate pace of 3.9%. Net earnings for the quarter were $859 million, a slight increase from $834 million in the prior year, resulting in diluted earnings per share of $2.22, up from $2.16. While overall operating income saw a marginal increase, the operating income margin slightly compressed due to various factors including integration costs from the Inari acquisition and increased selling, general, and administrative expenses. Despite these pressures, the company maintains a strong financial position with healthy cash flow from operations.

Oct 31, 2025 8-K

STRYKER CORP 8-K Report, Financial Results (Oct 30, 2025)

Stryker reported third quarter 2025 results on October 30, 2025 that beat on the top line and showed strong margin expansion, though reported earnings were roughly flat. Net sales rose 10.3% to $6.06 billion (9.5% organic), led by MedSurg and Neurotechnology, which grew 14.4% reported and 8.4% organic, helped by the Inari acquisition. Orthopaedics grew 3.9% reported but 11.4% organic, excluding the divested Spinal implant business. Reported operating margin was 18.7%, down from 19.7% a year earlier, because of acquisition-related charges, amortization of intangibles, and impairments. Adjusted operating margin expanded 90 bps to 25.6%, and adjusted EPS rose 11.1% to $3.19, while reported diluted EPS increased only 2.8% to $2.22. Management raised full-year 2025 guidance, now expecting organic sales growth of 9.8% to 10.2% and adjusted diluted EPS of $13.50 to $13.60. The guidance includes a modestly favorable pricing impact and a slightly positive FX effect if rates hold. The balance sheet shows the cost of the Inari deal: goodwill and intangibles rose to $25.1 billion from $20.3 billion, long-term debt increased to $14.8 billion from $12.2 billion, and nine-month acquisition spending was $4.95 billion. Nine-month reported net earnings declined 2.0% and operating income fell 0.7%, so investors will weigh the strength of adjusted results against the lower GAAP profitability and higher leverage.

Oct 30, 2025 10-Q

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2025

Stryker Corporation reported a solid performance for the second quarter of 2025, with total net sales increasing by 11.1% to $6,022 million compared to the same period in 2024. This growth was driven by robust performance in both the MedSurg and Neurotechnology segment (up 17.3%) and the Orthopaedics segment (up 2.0%), with strong contributions from increased unit volumes across most product lines. Net earnings for the quarter were $884 million, an increase from $825 million in the prior year, resulting in diluted earnings per share of $2.29, up from $2.14. The company made a significant strategic move in the first quarter by completing the acquisition of Inari Medical for $4,810 million, which is expected to bolster its Vascular business. While this acquisition, along with other integration-related costs, impacted operating expenses and the reported operating income margin, the company's adjusted operating income margin showed improvement. Stryker's strong operational execution and strategic acquisitions position it well for continued growth, although investors should monitor the impact of integration costs and macroeconomic factors.

Aug 1, 2025 8-K

STRYKER CORP 8-K Report, Financial Results (Jul 31, 2025)

Stryker reported strong second quarter 2025 results on July 31, 2025, with reported net sales up 11.1% to $6.0 billion and organic net sales up 10.2%, driven by 9.7% unit volume growth and 0.5% from pricing. MedSurg and Neurotechnology was the standout, growing 17.3% reported and 11.0% organic, led by Vascular (up 52.3% in the U.S., boosted by the Inari acquisition) and Endoscopy. Orthopaedics grew only 2.0% reported due to the divested Spinal implant business, but rose 9.0% organically and 10.7% excluding Spinal in the quarter. Reported diluted EPS rose 7.0% to $2.29, while adjusted EPS rose 11.4% to $3.13, and adjusted operating margin expanded 110 bps to 25.7%. Management raised full-year 2025 guidance, now expecting organic net sales growth of 9.5% to 10.0% and adjusted diluted EPS of $13.40 to $13.60. The company estimates a net 2025 tariff impact of about $175 million, lower than before due to reduced U.S.-China tariffs and the proposed U.S.-EU tariff framework. Reported results carry notable pressure: reported operating income for the six months fell 3.6%, reported net earnings fell 4.6%, and reported EPS declined 5.0%, mainly because of acquisition-related charges, amortization, and impairments. Balance sheet leverage rose sharply, with long-term debt climbing to $14.8 billion from $12.2 billion at year-end 2024, following about $4.8 billion of acquisition spending (including Inari). Cash fell to $2.4 billion, and inventories rose to $5.3 billion, a potential watch item.

Jul 31, 2025 8-K

STRYKER CORP 8-K Report, Executive Changes (May 13, 2025)

Stryker Corporation (SYK) held its Annual Meeting of Shareholders on May 8, 2025, where significant corporate governance and compensation-related proposals were approved. The most notable outcomes include the shareholder approval of the amended and restated 2011 Long-Term Incentive Plan, the 2011 Performance Incentive Award Plan, and the 2008 Employee Stock Purchase Plan. These approvals allow for an increase in the number of shares available for issuance under these plans and extend their durations, which is crucial for ongoing employee compensation and retention strategies. Additionally, all ten incumbent directors were re-elected, demonstrating continued shareholder confidence in the current board's leadership. The appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was also ratified. The advisory vote on executive compensation also received shareholder approval. These outcomes indicate shareholder alignment with the company's governance and compensation frameworks, suggesting stability and continued support for management's strategic direction.

May 13, 2025 10-Q

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2025

Stryker Corporation (SYK) reported its first-quarter 2025 results, showcasing robust top-line growth driven by strategic acquisitions and organic expansion. Net sales increased by 11.9% year-over-year to $5.87 billion, with constant currency growth of 12.8%. This growth was propelled by a 13.4% increase in the MedSurg and Neurotechnology segment and a 9.7% rise in the Orthopaedics segment. The company's profitability faced pressure from increased selling, general, and administrative expenses, largely due to acquisition-related costs, including a significant charge for Inari employee stock awards. As a result, net earnings decreased by 17.0% to $654 million, and diluted EPS fell to $1.69 from $2.05 in the prior year. However, adjusted EBITDA margin showed a healthier trend, indicating underlying operational strength. Financially, Stryker bolstered its liquidity through significant debt issuances, raising $2.98 billion in long-term debt. The company ended the quarter with a strong cash position, though it was reduced by substantial investing activities, primarily the Inari acquisition. The strategic acquisition of Inari, a leader in minimally invasive products for venous thromboembolism, is expected to enhance Stryker's Vascular business and drive future growth.

May 2, 2025 8-K

STRYKER CORP 8-K Report, Financial Results (May 1, 2025)

Stryker reported a solid first quarter 2025 with reported net sales up 11.9% to $5.9 billion (10.1% organic growth, 9.4% from unit volume), led by MedSurg and Neurotechnology (+13.4% reported, +10.7% organic) and Orthopaedics (+9.7% reported, +9.3% organic). Adjusted operating margin expanded 100 bps to 22.9% and adjusted EPS rose 13.6% to $2.84, while reported EPS fell 17.6% to $1.69 due to acquisition and integration charges, amortization of intangibles, impairments, and a $139 million stock compensation payment triggered by the Inari Medical change of control. Reported operating income declined 13.9% to $837 million, with reported operating margin of 14.3% versus 18.5% a year earlier. Management raised full-year 2025 organic net sales growth guidance to 8.5%-9.5%, citing strong demand for capital products and procedural volumes. Adjusted EPS guidance was lowered to $13.20-$13.45 from $13.45-$13.70, as management absorbed roughly $200 million of tariff impact, with the prior guidance already inclusive of Inari dilution of $0.20-$0.30 per share. The balance sheet changed materially: long-term debt rose to $14.4 billion from $12.2 billion, and goodwill and intangibles increased to $25.2 billion from $20.3 billion following the Inari acquisition, which required roughly $4.7 billion in cash. Cash and equivalents fell to $2.3 billion. Operating cash flow was $250 million, up from $204 million, though it remains modest relative to earnings given working capital build, including a $1.1 billion increase in inventories. Investors will likely focus on whether the tariff headwind is contained, the pace of Inari integration, and deleveraging.

May 1, 2025 8-K

STRYKER CORP 8-K Report, Material Agreement (Feb 27, 2025)

Stryker Corporation (SYK) has announced the execution of a new $3.0 billion revolving credit agreement, replacing its previous facility established in October 2021. This new agreement, effective February 25, 2025, extends the maturity date to February 25, 2030, providing long-term financial flexibility. A key feature is the introduction of an acquisition holiday provision, allowing a temporary increase in the maximum permitted leverage ratio to 4.75:1 from 3.75:1 in connection with material acquisitions, offering strategic agility for potential growth opportunities. While the underlying covenants and representations remain largely consistent with the prior agreement, the new credit facility outlines specific interest rates tied to various benchmarks (Eurocurrency Rate, Term SOFR, Term CORRA, or Base Rate) plus applicable margins, which are influenced by Stryker's credit ratings. The facility fee for undrawn amounts also varies based on credit ratings. This refinancing demonstrates Stryker's proactive approach to managing its capital structure and ensuring access to liquidity to support ongoing operations and strategic initiatives.

Feb 27, 2025 8-K

STRYKER CORP 8-K Report, Acquisition Completed (Feb 19, 2025)

Stryker Corporation (SYK) has officially announced the completion of its acquisition of Inari Medical, Inc. (Inari) as of February 19, 2025. This significant transaction, valued at approximately $4.94 billion in cash, was executed through a merger between Stryker's wholly owned subsidiary, Eagle 1 Merger Sub, Inc., and Inari. The acquisition was made under the terms of a previously announced Agreement and Plan of Merger dated January 6, 2025. This move represents a substantial strategic expansion for Stryker, likely aimed at bolstering its presence in a key medical device sector. Investors should monitor how the integration of Inari's business and products impacts Stryker's future revenue streams, profitability, and market share. The substantial cash outlay indicates a strong commitment to growth, and the success of this acquisition will be a key factor in evaluating Stryker's performance in the coming quarters and years.

Feb 19, 2025 10-K

STRYKER CORP Annual Report, Year Ended Dec 31, 2024

Stryker Corporation's 2024 10-K filing highlights a year of robust growth and strategic acquisitions, underscoring its position as a global leader in medical technologies. The company reported a 10.2% increase in net sales, reaching $22.595 billion, driven by strong performance across both its MedSurg and Neurotechnology (up 11.1%) and Orthopaedics (up 8.9%) segments. This growth was fueled by increased unit volumes and, to a lesser extent, higher pricing, demonstrating resilience in a dynamic healthcare market. The company also completed several strategic acquisitions totaling $1.628 billion, further expanding its product portfolios and market reach. Financially, Stryker maintained healthy profitability with a gross profit margin of 63.9%. However, net earnings saw a slight decrease to $2.993 billion from $3.165 billion in the prior year, partly due to significant goodwill impairments related to its Spine business, amounting to $456 million, and a $362 million loss recognized on assets held for sale within the Spinal Implants business. Despite these charges, operating income remained strong. The company continued its commitment to capital allocation, investing in acquisitions, paying $1.219 billion in dividends, and maintaining a strong liquidity position with $3.743 billion in cash, cash equivalents, and marketable securities.

Feb 12, 2025 8-K

STRYKER CORP 8-K Report, Executive Changes (Feb 10, 2025)

Stryker Corporation (SYK) has announced a director change in a recent 8-K filing. Allan Golston, a long-standing member of the Board of Directors, has informed the company of his intention to retire from the Board. His retirement is set to be effective at the upcoming annual meeting of shareholders, anticipated on May 8, 2025. Mr. Golston will continue his directorial duties until that date. Importantly, the company has stated that Mr. Golston's decision to retire is not a result of any disagreements with the Company's management or its operations. This indicates a planned and orderly transition, which is generally viewed positively by investors as it avoids potential governance concerns. Investors should note this change as part of the ongoing board composition and governance updates for Stryker.

Feb 10, 2025 8-K

STRYKER CORP 8-K Report, Material Agreement (Feb 10, 2025)

Stryker Corporation (SYK) announced the completion of a significant public offering of senior notes, raising a total of $3 billion. This offering consists of four tranches with varying maturities and interest rates: $500 million of 4.550% Notes due 2027, $700 million of 4.700% Notes due 2028, $800 million of 4.850% Notes due 2030, and $1 billion of 5.200% Notes due 2035. The proceeds from the issuance will be strategically allocated, with the 2030 and 2035 Notes intended to fund the tender offer for the acquisition of Inari Medical, Inc., and related expenses. The proceeds from the 2027 and 2028 Notes will be used for general corporate purposes, including working capital and potential acquisitions. The filing also outlines certain conditions related to the Inari Medical acquisition, specifically regarding the 2030 and 2035 Notes. Should the Inari acquisition not be consummated under specified terms by a certain date, these particular notes will be subject to a special mandatory redemption at 101% of their principal amount plus accrued interest. This structure highlights the company's commitment to its strategic growth initiatives while managing financial obligations and potential deal contingencies.

Feb 10, 2025 8-K

STRYKER CORP 8-K Report, Executive Changes (Jan 28, 2025)

Stryker (NYSE: SYK) announced on January 28, 2025 a planned leadership change in its finance function. Glenn S. Boehnlein, Vice President and Chief Financial Officer, will retire effective April 1, 2025, after a 22-year career at the company. He will then serve as Advisor to the Chief Executive Officer through March 31, 2026 under a Transition Agreement, during which he keeps his $800,000 base salary, a 2025 bonus target of 100%, and a $215,000 advisory-period bonus conditioned on staying through the transition. He will receive no new equity awards during that period. Preston W. Wells, currently Vice President and Group CFO for the Orthopaedics Group, will succeed him as Vice President and Chief Financial Officer effective the same date. Wells has been with Stryker since 2015 and previously led Investor Relations and Enterprise FP&A, which gives him direct exposure to the investor community and company-wide planning. His base salary rises to $725,000, his bonus target is 85% of salary (prorated for 2025), and the Compensation Committee is expected to consider a February 2025 long-term incentive grant with an aggregate target value of about $3.0 million (40% stock options, 60% performance stock units). For investors, the filing describes an orderly, planned succession with an internal candidate and a multi-month overlap period, which generally reduces execution risk. The filing does not discuss any change to financial guidance, results, or strategy, and the press release attributes the decision to Boehnlein's personal choice rather than any performance issue.

Jan 28, 2025 8-K

STRYKER CORP 8-K Report, Financial Results (Jan 28, 2025)

Stryker's fourth-quarter and full-year 2024 results show strong top-line momentum with underlying profitability improving, but GAAP earnings were hit hard by impairments tied to the Spine business. Q4 reported net sales rose 10.7% to $6.4 billion (10.2% organic), and full-year net sales reached $22.6 billion, up 10.2% (10.2% organic). Adjusted operating margin expanded 200 bps in Q4 to 29.2% and 110 bps for the year to 25.3%, with adjusted EPS up 15.9% to $4.01 in Q4 and 15.0% to $12.19 for the year. Reported results were materially depressed by $818 million of non-cash charges related to Spine, including a $273 million goodwill impairment from the annual test and a further $183 million goodwill impairment plus a $362 million asset impairment after the Spinal Implants business was classified as held for sale. Q4 reported diluted EPS fell 52.7% to $1.41, and full-year reported EPS declined 5.9% to $7.76. Investors should focus on the adjusted metrics with the understanding that the Spine divestiture and impairments represent a real write-down of that franchise. For 2025, management guided to organic net sales growth of 8.0% to 9.0% and adjusted diluted EPS of $13.45 to $13.70, with FX expected to reduce net sales by about 1% and EPS by $0.10 to $0.15. The guidance excludes the pending Inari Medical acquisition, expected to close around late February, which is projected to add roughly $590 million of stub-period sales and dilute adjusted operating margin by 0 to 20 bps and adjusted EPS by $0.20 to $0.30. Balance sheet leverage increased, with long-term debt rising to $12.2 billion from $10.9 billion, reflecting acquisition funding.

Jan 28, 2025 8-K

STRYKER CORP 8-K Report, Material Agreement (Jan 7, 2025)

On January 6, 2025, Stryker (SYK) entered into a Merger Agreement to acquire Inari Medical (NARI) for $80.00 per share in cash, implying a fully diluted equity value of approximately $4.9 billion. The deal is structured as a two-step transaction: a tender offer by a Stryker subsidiary, followed by a Section 251(h) merger to acquire any remaining shares at the same price. Stryker's stated rationale is to expand its portfolio into peripheral vascular disease, particularly venous thromboembolism (VTE), a segment the company describes as high-growth, and to complement its Neurovascular business with Inari's non-thrombolytic mechanical thrombectomy products. Closing is conditioned on a majority minimum tender, expiration or termination of the HSR waiting period, and the absence of legal restraints. The offer must initially remain open for at least 20 business days and can be extended in 10-business-day increments, with a cap of three extensions where the Minimum Tender Condition is the only unmet condition. The merger agreement's End Date is July 7, 2025, automatically extendable to October 6, 2025 if only regulatory or legal-restraint conditions remain. Inari would owe Stryker a $163 million termination fee in specified circumstances, including accepting a superior proposal or a change in its board's recommendation. Stryker expects the transaction to close by the end of the first quarter of 2025 and will discuss expected impacts on 2025 financial results on its Q4 2024 earnings call on January 28, 2025. For investors, the filing is primarily a deal announcement with limited quantitative disclosure about Stryker's financing, purchase accounting, or pro forma effects. Key items to monitor include the HSR review outcome, tender participation levels, and Stryker's 2025 guidance update, which will indicate how the acquisition is expected to affect earnings and margins.

Jan 7, 2025 10-Q

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2024

Stryker Corporation reported a strong third quarter for fiscal year 2024, demonstrating robust top-line growth and improved profitability. Net sales increased by 11.9% year-over-year, driven by solid performance in both the MedSurg and Neurotechnology, and Orthopaedics and Spine segments, with particularly strong unit volume increases across most product lines. The company also showed improved operational efficiency, with operating income growing faster than net sales. Net earnings per diluted share rose by 20.0% year-over-year. Stryker continued to invest in growth through strategic acquisitions and development, while also managing its financial leverage effectively through debt issuance and managing cash flow from operations. Investors should note the company's ongoing focus on innovation and strategic M&A as key drivers of future performance, alongside the management's confidence in its financial health and ability to meet liquidity needs.

Oct 30, 2024 8-K

STRYKER CORP 8-K Report, Financial Results (Oct 29, 2024)

Stryker reported third quarter 2024 results on October 29, 2024 that were strong on both the top and bottom lines. Reported net sales rose 11.9% to $5.5 billion (11.5% organic, 12.0% constant currency), led by MedSurg and Neurotechnology at +12.7% organic and Orthopaedics and Spine at +9.7% organic. Organic growth was driven mainly by unit volume (10.3%), with a modest contribution from price (1.2%). Reported EPS grew 20.0% to $2.16, while adjusted EPS grew 16.7% to $2.87, and adjusted operating margin expanded 130 bps to 24.7%. Part of the quarter's extra selling day and the acquisition contribution (0.5 points) also supported reported growth. Management raised its full-year 2024 outlook. Organic net sales growth is now guided to 9.5%–10.0% (up from prior expectations, with pricing contributing 0.5%–1.0%), and adjusted EPS guidance is $12.00–$12.10. Management noted that the expected FX impact (about $0.10 on EPS) is already reflected. Management also reiterated that it is on track for its adjusted operating margin expansion goals. Investors should keep an eye on the balance sheet and the quality of earnings. Long-term debt rose to $13.3 billion from $10.9 billion at year-end 2023, reflecting acquisition funding, and goodwill and intangibles climbed to $21.3 billion. Nine-month acquisition spending was $1.6 billion, and inventories increased to $5.3 billion. Reported operating cash flow was $2.3 billion for the nine months, up modestly year over year, while the gap between reported and adjusted results remains significant, largely because of amortization of purchased intangibles and recurring structural optimization charges. The filing is furnished rather than filed under Item 2.02, and it contains forward-looking statements subject to risks including pricing pressure, FX, regulatory actions, recall-related costs and integration of acquisitions.

Oct 29, 2024 8-K

STRYKER CORP 8-K Report, Material Agreement (Sep 11, 2024)

Stryker Corporation (SYK) has announced the successful completion of two significant public offerings of senior notes, raising a total of approximately €1.4 billion (or $1.53 billion USD) in Euro Notes and $1.5 billion USD in U.S. Dollar Notes. The Euro Notes consist of €800 million of 3.375% Notes due 2032 and €600 million of 3.625% Notes due 2036. The U.S. Dollar Notes comprise $750 million of 4.250% Notes due 2029 and $750 million of 4.625% Notes due 2034. The net proceeds from these offerings are earmarked for significant corporate actions. Primarily, the funds will be used to repay €500 million of floating rate notes due 2024 and €850 million of 0.250% notes due 2024 at maturity. The remaining proceeds will be allocated to general corporate purposes, including working capital, potential acquisitions, and other business opportunities, as well as further debt repayment or retirement. This move indicates active management of Stryker's capital structure and strategic financial planning.

Sep 11, 2024 10-Q

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2024

Stryker Corporation (SYK) reported strong financial performance for the second quarter and first half of 2024, demonstrating robust top-line growth and improved profitability. Net sales increased by 8.5% to $5.42 billion for the quarter and 9.1% to $10.67 billion for the first half, driven by solid unit volume increases across both the MedSurg and Neurotechnology and Orthopaedics and Spine segments. This growth was achieved despite ongoing macroeconomic challenges such as inflation and supply chain disruptions. Profitability metrics also showed positive trends. Gross profit margin remained strong, and operating income saw significant increases, particularly in the MedSurg and Neurotechnology segment. Diluted earnings per share (EPS) rose to $2.14 for the quarter and $4.19 for the six-month period, reflecting the company's operational efficiency and strategic execution. Stryker's balance sheet remains healthy, with ample liquidity to support ongoing operations and strategic initiatives, including acquisitions.

Jul 31, 2024 8-K

STRYKER CORP 8-K Report, Financial Results (Jul 30, 2024)

Stryker (SYK) reported second quarter 2024 results that beat the top-line and earnings trend, with reported net sales up 8.5% to $5.4 billion (9.4% in constant currency and 9.0% organic). Growth was broad-based: MedSurg and Neurotechnology sales rose 9.0% to $3.1 billion (9.7% organic), and Orthopaedics and Spine rose 7.9% to $2.3 billion (8.0% organic). Organic growth was driven mainly by unit volume (7.9%), with a modest 1.1% contribution from price. Reported diluted EPS rose 10.9% to $2.14, and adjusted diluted EPS rose 10.6% to $2.81. Adjusted operating margin expanded 30 bps to 24.6%, consistent with management's margin expansion goals. Management raised its full-year 2024 guidance. Organic net sales growth is now expected at 9.0% to 10.0%, with a favorable pricing impact of about 0.5%. Adjusted diluted EPS guidance is $11.90 to $12.10, which reflects an expected $0.10 to $0.15 headwind from foreign exchange if current rates hold. Management cited sustained procedural volumes and healthy demand for capital products as the basis for the outlook. On the balance sheet, cash fell to $1.9 billion from $3.0 billion at year-end 2023, as debt repayments of $600 million and dividends of $609 million outweighed operating cash flow. Operating cash flow for the first half was $837 million, down from $1.13 billion a year earlier, mainly due to a $1.29 billion working capital and other outflow. Inventories rose to $5.0 billion. Long-term debt declined to $10.1 billion, and shareholders' equity increased to $19.8 billion. Investors may want to monitor working capital normalization and cash conversion in coming quarters.

Jul 30, 2024 8-K

STRYKER CORP 8-K Report, Shareholder Vote Results (May 14, 2024)

At Stryker Corp.'s Annual Meeting of Shareholders held on May 9, 2024, shareholders elected all ten directors to serve until the next Annual Meeting and until their successors are duly elected and qualified. Each director received more For votes than Against votes, with Rachel Ruggeri receiving 304,909,652 For and 428,014 Against and Kevin A. Lobo receiving 291,946,719 For and 12,953,199 Against. Shareholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2024, with 306,622,353 votes For and 25,829,393 Against. Shareholders approved, on an advisory basis, the compensation of the named executive officers, with 277,838,598 votes For, 27,264,023 Against and 627,454 Abstain, plus 27,028,775 broker non-votes. The shareholder proposal related to transparency in political spending was not approved, receiving 113,859,053 For and 190,289,960 Against, with 1,581,062 Abstain and 27,028,775 broker non-votes. The filing is limited to the results of these four matters submitted to a shareholder vote at the annual meeting under Item 5.07, and it reports no other corporate actions.

May 14, 2024 10-Q

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2024

Stryker Corporation reported a strong first quarter for 2024, demonstrating robust top-line growth and improved profitability. Net sales increased by 9.7% year-over-year to $5.24 billion, driven by solid performance in both the MedSurg and Neurotechnology and Orthopaedics and Spine segments. This growth was primarily attributed to increased unit volume across all businesses, with pricing also contributing positively. The company also achieved a significant increase in net earnings, rising 33.1% to $788 million, with diluted EPS growing to $2.05 from $1.54 in the prior year period. The company's operational efficiency improved, with gross profit margin increasing to 63.6% and operating income margin expanding to 18.5%. This was supported by favorable volume dynamics and easing inflationary pressures on manufacturing costs. Stryker also made a strategic acquisition of SERF SAS for $246 million, strengthening its Joint Replacement business. Despite ongoing macroeconomic uncertainties, including inflation and higher interest rates, Stryker's financial position remains strong, with healthy liquidity and a positive outlook for continued growth.

May 1, 2024 8-K

STRYKER CORP 8-K Report, Financial Results (Apr 30, 2024)

Stryker (SYK) reported a strong first quarter 2024 on April 30, 2024, with reported net sales up 9.7% to $5.2 billion and organic net sales up 10.0%, driven by 9.3% unit volume growth and 0.7% price. MedSurg and Neurotechnology was the standout, growing 11.5% reported (11.6% organic), while Orthopaedics and Spine grew 7.5% reported (8.0% organic). Profitability improved meaningfully: reported operating margin rose to 18.5% from 15.4%, adjusted operating margin expanded 80 bps to 21.9%, and reported diluted EPS climbed 33.1% to $2.05. Adjusted diluted EPS grew 16.8% to $2.50, though the reported EPS gain was flattered by a $41 million net tax benefit from discrete tax matters, so investors should focus on the adjusted figures for underlying trends. Management raised its full-year 2024 organic sales growth outlook to 8.5%-9.5% (pricing roughly flat) and set adjusted diluted EPS guidance at $11.85-$12.05, up from the prior range. Management noted that foreign exchange is expected to moderately reduce reported net sales, weighing more heavily in the first half, and to pressure adjusted EPS toward the higher end of the previously guided $0.05-$0.10 headwind. Operating cash flow was weak at $204 million versus $445 million a year earlier, driven by a $844 million outflow from working capital changes, with inventories and receivables movements being the key drivers of the shortfall. Overall, the quarter shows broad-based demand, solid volume-led growth, and margin expansion, supporting a constructive view on the raised guidance. The main watch items are the cash conversion shortfall, FX headwinds, and the reliance on non-GAAP measures to show underlying earnings growth.

Apr 30, 2024 10-K

STRYKER CORP Annual Report, Year Ended Dec 31, 2023

Stryker Corporation's 2023 10-K filing highlights robust top-line growth driven by strong unit volume increases across its MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The company reported net sales of $20.5 billion, an increase of 11.1% year-over-year, with constant currency growth at 11.6%. This growth was supported by product innovation and market expansion, including the acquisition of Cerus Endovascular. Profitability showed improvement, with operating income rising significantly, reflecting effective cost management and favorable pricing, though offset by increased manufacturing and supply chain costs. Stryker continues to prioritize its capital allocation strategy, investing in acquisitions, returning capital to shareholders through dividends, and engaging in share repurchases. The company maintains a strong liquidity position, with substantial cash from operations and access to credit markets. Key operational risks identified include supply chain disruptions, inflationary pressures, pricing pressures within the healthcare industry, and regulatory compliance. The company's robust risk management framework, including cybersecurity, is actively overseen by management and the Board of Directors.

Feb 14, 2024 8-K

STRYKER CORP 8-K Report, Financial Results (Jan 30, 2024)

Stryker closed 2023 with strong top-line momentum and solid profitability. Fourth-quarter net sales rose 11.8% to $5.8 billion (11.4% organic), and full-year net sales reached $20.5 billion, up 11.1% reported and 11.5% organic, crossing the $20 billion milestone. Growth was broad-based: MedSurg and Neurotechnology grew 11.8% organically for the year and Orthopaedics and Spine grew 11.1%, with volume driving most of the increase and price contributing roughly 0.6% to 0.7%. Reported full-year diluted EPS rose 33.7% to $8.25, while adjusted EPS grew 13.5% to $10.60. Adjusted operating margin expanded 40 bps to 24.2%, and the reported gap versus adjusted results mainly reflects amortization of purchased intangibles, structural optimization charges, and regulatory and legal items. Management guided 2024 organic net sales growth of 7.5% to 9.0% and adjusted diluted EPS of $11.70 to $12.00, implying roughly 10% to 13% adjusted EPS growth. Pricing is expected to be roughly flat for the full year, and unfavorable foreign exchange is expected to modestly reduce sales and reduce EPS by about $0.05 to $0.10, with the sales impact weighted toward the first half. The guidance reflects management's view of strong procedure volumes, healthy capital demand, and a stabilizing macro environment, though the company flags risks including pricing pressure, supply chain disruption, regulatory actions, product liability, recall costs, and cyber threats. Cash flow strengthened meaningfully, with operating cash flow of $3.68 billion versus $2.62 billion in 2022 and capital expenditures of $575 million. Inventories rose to $4.84 billion from $4.0 billion, a build that merits monitoring against sales growth. Long-term debt declined to $10.9 billion from $11.9 billion, and shareholders' equity increased to $18.6 billion. Note that this filing is the earnings press release furnished under Item 2.02 and is not a full financial statement filing; the figures are unaudited.

Jan 30, 2024 8-K

STRYKER CORP 8-K Report, Material Agreement (Dec 11, 2023)

Stryker Corporation (SYK) has announced the completion of a public offering of €600,000,000 aggregate principal amount of its 3.375% Notes due 2028. The offering, which closed on December 11, 2023, utilized the company's existing shelf registration statement and prospectus. The net proceeds are expected to be approximately €597 million (or $649 million based on the specified exchange rate), which Stryker intends to use for general corporate purposes. These new notes carry a fixed annual interest rate of 3.375%, with interest payments due annually on December 11, commencing in 2024, and the principal maturing on December 11, 2028. The indenture governing these notes includes covenants that restrict certain actions like incurring additional liens or engaging in sale-and-leaseback transactions. Importantly, a change of control event, coupled with a downgrade to below investment grade by both Moody's and S&P, would trigger an offer to repurchase the notes at 101% of the principal amount.

Dec 11, 2023 8-K

STRYKER CORP 8-K Report, Material Agreement (Dec 8, 2023)

Stryker Corporation (SYK) announced on December 8, 2023, the completion of a public offering of $600 million in aggregate principal amount of 4.850% Notes due 2028. The company expects to receive net proceeds of approximately $594 million, which will be used for general corporate purposes. This debt issuance adds to Stryker's capital structure and provides financial flexibility for its ongoing operations and strategic initiatives. In addition to the debt offering, the company disclosed that Dr. Srikant Datar, a member of the Board of Directors, will retire from the Board effective as of the company's annual meeting of shareholders expected to be held on May 9, 2024. This departure is not a result of any disagreement with the company. Investors should monitor how these proceeds are deployed and assess any potential impact of Dr. Datar's departure on board dynamics.

Dec 8, 2023 10-Q

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2023

Stryker Corporation reported strong top-line growth in the third quarter of 2023, with net sales increasing by 9.6% year-over-year to $4.91 billion, driven by both increased unit volume and higher pricing across its major business segments. The company demonstrated improved profitability, with gross profit margin expanding to 64.3% from 62.1% in the prior year's quarter, largely due to favorable volume, mix, and cost efficiencies. Net earnings, however, saw a decrease to $692 million from $816 million in the prior year, resulting in diluted EPS of $1.80 compared to $2.14. This decline in net earnings was influenced by various factors including increased selling, general, and administrative expenses as a percentage of sales and other income/expense fluctuations. The nine-month performance also showcased robust sales growth of 10.8% to $14.68 billion. The company maintained its focus on strategic investments, including the acquisition of Cerus Endovascular Limited, and managing its debt obligations, repaying a significant portion of its term loan. Despite the reported decrease in net earnings for the quarter, the company's underlying operational performance, particularly in sales and gross profit, indicates continued strength and expansion in key markets.

Nov 3, 2023 8-K

STRYKER CORP 8-K Report, Financial Results (Nov 2, 2023)

Stryker reported third quarter 2023 results with net sales of $4.9 billion, up 9.6% reported and 9.2% organic, driven by 8.9% unit volume growth and 0.3% price. MedSurg and Neurotechnology grew 10.5% reported to $2.9 billion, and Orthopaedics and Spine grew 8.4% to $2.1 billion. Adjusted operating margin expanded 110 bps to 23.4%, and adjusted EPS rose 16.0% to $2.46. Reported EPS fell 15.9% to $1.80 and net earnings declined 15.2% to $692 million. The gap reflects a prior-year tax benefit (Q3 2022 income taxes were zero, versus $177 million in Q3 2023), higher amortization of intangibles, and higher other expense. Management raised its full-year 2023 guidance to 10.0% to 10.5% organic sales growth and adjusted EPS of $10.35 to $10.45, citing a robust capital equipment backlog and positive procedural trends. The quarter also shows some items investors should monitor. Inventories rose to $4.88 billion from $3.99 billion at year-end 2022, a roughly 22% increase that outpaces sales growth. Selling, general and administrative expenses grew 16.9% reported, while reported gross margin improved to 64.3%. Nine-month operating cash flow improved to $2.18 billion from $1.62 billion, and long-term debt declined to $10.38 billion from $11.86 billion. Management also noted a tailwind from one fewer selling day in the prior-year period was not present in the nine-month comparison, and foreign exchange is expected to reduce full-year sales by about 0.6% and adjusted EPS by $0.10 to $0.15. Overall, the filing points to strong top-line momentum and margin expansion on an adjusted basis, with a meaningful gap between adjusted and GAAP earnings. Investors will likely focus on whether the inventory build reflects demand for capital equipment and new products, and on the sustainability of margin gains as amortization and other charges continue.

Nov 2, 2023 10-Q

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2023

Stryker Corporation (SYK) reported strong financial performance for the second quarter and first half of 2023, driven by significant net sales growth across both its MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The company demonstrated robust top-line expansion, with total net sales increasing by 11.2% in the quarter and 11.5% year-to-date on a reported basis, translating to 11.9% and 12.9% growth in constant currency, respectively. This growth was primarily fueled by increased unit volumes across its businesses, with price increases contributing a smaller, though positive, portion. Profitability metrics also showed improvement. Gross profit margin increased to 63.7% in the second quarter from 62.9% in the prior year, reflecting favorable sales pricing, volume, and mix, partially offset by manufacturing and supply chain costs. Operating income saw a substantial increase, rising to $965 million (19.3% margin) in the quarter and $1,700 million (17.4% margin) year-to-date, up from $772 million (17.2% margin) and $1,219 million (13.9% margin) respectively in the prior year. Diluted earnings per share (EPS) reached $1.93 for the quarter and $3.47 for the six months, a notable increase from $1.72 and $2.56 in the comparable periods of 2022. The company also reported healthy cash flow from operations, underscoring its financial strength and operational efficiency.

Aug 4, 2023 8-K

STRYKER CORP 8-K Report, Financial Results (Aug 3, 2023)

Stryker reported strong second quarter 2023 results, with reported net sales up 11.2% to $5.0 billion and organic net sales up 11.9%, driven by 11.4% unit volume growth and 0.5% from higher prices. Both segments grew, with MedSurg and Neurotechnology up 12.2% reported (12.9% organic) to $2.9 billion and Orthopaedics and Spine up 9.9% reported (10.6% organic) to $2.1 billion. Growth was broad across geographies, with U.S. sales up 12.1% and international sales up 8.7% reported (11.5% constant currency). Management attributed the performance to strong demand, a solid capital equipment order book, and positive procedural trends. Profitability improved meaningfully. Reported operating margin rose to 19.3% from 17.2%, and adjusted operating margin expanded 60 bps year over year to 24.3%. Reported diluted EPS grew 12.2% to $1.93, while adjusted diluted EPS rose 12.9% to $2.54. Management said the company is "back on our margin expansion pathway." Inventories rose sharply to $4.6 billion from $4.0 billion at year-end 2022, which is worth monitoring alongside the strong sales. Operating cash flow for the first half improved to $1.13 billion from $732 million, although net debt-related cash outflows and acquisitions also shaped the cash position. Looking ahead, Stryker raised its full-year 2023 guidance. It now expects organic net sales growth of 9.5% to 10.5%, including slightly positive pricing, and adjusted diluted EPS of $10.25 to $10.45. Management expects foreign exchange to reduce net sales by about 0.3% and adjusted EPS by $0.05 to $0.10. The company furnished this information under Item 2.02 and did not file it, so it is not subject to Section 18 liability unless specifically incorporated by reference.

Aug 3, 2023 8-K

STRYKER CORP 8-K Report, Material Agreement (Jun 16, 2023)

Stryker Corporation (SYK) has filed an 8-K report on June 15, 2023, to announce an amendment to its existing Credit Agreement originally dated October 26, 2021. This amendment, effective June 15, 2023, primarily transitions the credit facility from LIBOR-based benchmark interest rates to SOFR-based benchmark rates. This is a standard market practice as LIBOR is being phased out globally.

Jun 16, 2023 8-K

STRYKER CORP 8-K Report, Shareholder Vote Results (May 16, 2023)

This 8-K filing from Stryker Corporation details the outcomes of its Annual Meeting of Shareholders held on May 10, 2023. The key takeaway for investors is the overwhelming shareholder support for the company's proposed actions. All ten nominated directors were overwhelmingly elected, indicating strong confidence in the current board's leadership and governance. Furthermore, shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2023, a crucial vote for maintaining financial transparency and integrity. The advisory vote on executive compensation, often a point of scrutiny for investors, also received strong approval, suggesting satisfaction with the company's compensation practices. Shareholders also overwhelmingly supported holding an annual advisory vote on executive compensation, aligning with the Board's recommendation and indicating a preference for regular shareholder input on this matter. The only proposal that did not pass was a shareholder proposal related to political disclosure, which received significant opposition.

May 16, 2023 10-Q

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2023

Stryker Corporation reported strong first-quarter 2023 results, with net sales increasing by 11.8% to $4.78 billion, demonstrating robust top-line growth. This increase was driven by a balanced contribution from both the MedSurg and Neurotechnology and Orthopaedics and Spine segments, with constant currency growth of 14.0% highlighting operational strength. Diluted Earnings Per Share (EPS) saw a significant jump to $1.54, more than doubling from $0.84 in the prior year's quarter, reflecting improved profitability. The company also highlighted strategic progress, including the recent acquisition of Cerus Endovascular Limited, aimed at bolstering its neurovascular offerings. Despite facing ongoing macroeconomic challenges such as inflation and supply chain constraints, Stryker's management expressed confidence in its ability to navigate these headwinds, supported by solid operational execution and strategic investments. The company's financial condition remains strong, with ample liquidity to support ongoing operations and future growth initiatives.

May 2, 2023 8-K

STRYKER CORP 8-K Report, Financial Results (May 1, 2023)

Stryker reported first quarter 2023 results with reported net sales up 11.8% to $4.8 billion and organic net sales up 13.6%, driven by 12.9% unit volume growth and 0.7% price. Growth was broad-based: Orthopaedics and Spine organic sales rose 15.2% and MedSurg and Neurotechnology rose 12.4%, while International sales grew 16.5% in constant currency versus 8.2% as reported, reflecting a roughly 8-point foreign exchange headwind. Reported operating margin expanded to 15.4% from 10.5%, and reported diluted EPS rose 83.3% to $1.54. However, the comparison is flattered by a $2.56 billion acquisition-related cash outflow in Q1 2022 and by lower one-time charges in 2023, so the reported EPS jump overstates underlying improvement. On an adjusted basis, operating margin contracted 70 bps to 21.1% and adjusted EPS rose 8.6% to $2.14, indicating that cost pressure, including higher inventory and supply chain costs, weighed on profitability even as volumes recovered. Operating cash flow improved to $445 million from $203 million, though it was supported by lower acquisition spending rather than strong operating earnings, and inventories rose to $4.33 billion from $3.995 billion at year-end, a development investors should monitor. Management raised its full-year 2023 guidance, now expecting organic net sales growth of 8.0% to 9.0% and adjusted diluted EPS of $10.05 to $10.25, and expects pricing to be roughly neutral for the year. Management cited a strong capital equipment order book and ongoing procedural recovery. Foreign exchange is expected to modestly reduce sales and EPS, with a greater impact in the first half. The information is furnished under Item 2.02 and is not deemed filed for Exchange Act purposes.

May 1, 2023